2022-09-13T14:28:45-05:00 2021-12-31 390974031 WEGNER CPAS LLP 419 N LEE ST ALEXANDRIA VA 223142301 990 2021-01-01 821199380 GLOBAL COALITION FOR ADAPTIVE RESEARCH INC GLOB 6172996471 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391715 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER 6172996471 2022-09-13 1 MEREDITH BUXTON 999009999 GLENN MILLER CPA P00086726 7035190990 2022-09-08 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z MEREDITH BUXTON 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391715 38719697 0 X GCARESEARCH.ORG X 2017 MD TO SPEED THE DISCOVERY AND DEVELOPMENT OF TREATMENTS FOR PATIENTS WITH RARE AND DEADLY DISEASES BY SERVING AS SPONSOR OF INNOVATIVE TRIALS. 8 6 22 7 0 0 365772 504130 15491428 38210063 5866 5504 0 0 15863066 38719697 250000 0 0 0 1487022 2873252 0 0 0 8715223 16329913 10452245 19203165 5410821 19516532 28309589 40740875 23032332 13880420 5277257 26860455 OUR MISSION IS TO SPEED THE DISCOVERY AND DEVELOPMENT OF TREATMENTS FOR PATIENTS WITH RARE AND DEADLY DISEASES BY SERVING AS SPONSOR OF INNOVATIVE TRIALS. 0 0 13775975 33019636 GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS. 2936071 3356550 THE OBJECTIVE OF REMAP-COVID IS TO REDUCE MORTALITY AND MORBIDITY IN PATIENTS HOSPITALIZED WITH COVID-19 INFECTION BY QUICKLY GENERATING NEW EVIDENCE ON AVAILABLE AND NOVEL TREATMENTS. THROUGH PARTNERSHIPS WITH ACADEMIA, INDUSTRY AND MULTIPLE HEALTHCARE SYSTEMS, GCAR IS SPONSORING REMAP-COVID IN THE US WITH THE UNIVERSITY OF PITTSBURGH SERVING AS THE US REGIONAL COORDINATING CENTER FOR REMAP-CAP. 1931151 1833877 OTHER- SMALLER OR TEMPORARY PROGRAMS AS WELL AS PROGRAMS IN DEVELOPMENT FOR GLOBAL COALITION FOR ADAPTIVE RESEARCH. 18643197 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 7 0 22 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X JENNIFER HOFFMAN 6617144010 700 LARKSPUR LANDING CIRCLE STE 199 LARKSPUR CA 949391715 GARY GORDON PRESIDENT AND DIRECTOR 4.00 X X 84000 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 8.00 X X 120000 0 0 FARAMARZ YOUSEFZADEH CHAIRMAN OF THE BOARD 1.00 X X 0 0 0 JOHN FRISHKOPF DIRECTOR 1.00 X 0 0 0 BRIAN ALEXANDER MD DIRECTOR 1.00 X 0 0 0 WK ALFRED YUNG MD DIRECTOR 1.00 X 0 0 0 WEBSTER CAVENEE PHD DIRECTOR 1.00 X 0 0 0 SUJUAN BA PHD DIRECTOR 1.00 X 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER 40.00 X 525000 0 44393 ROBERT MURRAY CHIEF BUSINESS OFFICER 40.00 X 399635 0 9975 ASHLEY POWELL EXECUTIVE DIRECTOR OF TRIAL OPERATIONS 40.00 X 225000 0 7745 TRACEY ROBERTS CLINICAL OPERATIONS LEAD 40.00 X 161250 0 15827 APOORVA NELLI CLINICAL SCIENTIST 40.00 X 149500 0 13691 RYKAE COOPER CLINICAL OPERATIONS LEAD 40.00 X 126500 0 12757 RACHEL ROSENSTEIN-SISSON SENIOR DIRECTOR OF ADMINISTRATION 40.00 X 125000 0 11988 1915885 0 116376 10 0 1 0 IQVIA 1700 PERIMETER PARK DR MORRISVILLE NC 27560 CLINICAL RESEARCH 11844218 MEDIDATA 350 HUDSON ST 9TH FLOOR NEW YORK NY 10014 CLINICAL RESEARCH 305719 BERRY CONSULTANTS 3345 BEE CAVES RD STE 201 AUSTIN TX 78746 CLINICAL RESEARCH 238200 3 504130 504130 TRIAL REVENUE 541700 38210063 38210063 38210063 5504 5504 38719697 38210063 0 5504 X 1183003 1034403 148600 1372103 1199748 172355 30256 26455 3801 138174 120818 17356 149716 130910 18806 237062 211583 25479 55613 55613 15380341 15378879 1462 15060 1122 13938 86087 6413 79674 2077 155 1922 10219 761 9458 18385 14632 3753 43605 35854 7751 PROGRAM SUPPLIES 481464 481464 19203165 18643197 559968 0 28140238 5668875 127365 30360174 4551658 41986 160168 28309589 40740875 1341423 3469813 20190909 8910607 1500000 1500000 23032332 13880420 X 5277257 26860455 5277257 26860455 28309589 40740875 19516532 2066666 0 X 0 1 X 1 0 X 1525750 662857 365772 504130 3058509 1525750 662857 365772 504130 3058509 3058509 2303 5866 5504 13673 3072182 65951491 X SCHEDULE A, PART II THE 2017 COLUMN OF SCHEDULE A, PART II IS FOR THE INITIAL YEAR OF APRIL 12, 2017 TO DECEMBER 31, 2017. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 REFUNDABLE ADVANCE 1500000 1500000 38870334 150637 150637 38719697 0 38719697 19353802 150637 150637 19203165 0 19203165 X X 0 0 0 0 0 0 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER 375000 0 150000 0 0 0 11344 0 33049 0 569393 0 0 0 ROBERT MURRAY CHIEF BUSINESS OFFICER 224635 0 175000 0 0 0 9075 0 900 0 409610 0 0 0 ASHLEY POWELL EXECUTIVE DIRECTOR OF TRIAL OPERATIO 180000 0 45000 0 0 0 6845 0 900 0 232745 0 0 0 TRACEY ROBERTS CLINICAL OPERATIONS LEAD 146250 0 15000 0 0 0 2963 0 12864 0 177077 0 0 0 APOORVA NELLI CLINICAL SCIENTIST 130000 0 19500 0 0 0 5200 0 8491 0 163191 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B CHAIRMAN OF THE BOARD REVIEWS WITH ACCOUNTING FIRM. ONCE FORM IS COMPLETE, FORM IS REVIEWED WITH THE ENTIRE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ON AN ANNUAL BASIS. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IN THE COMPANY DATABASE IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. ANY BOARD MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVANT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVANT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS IS RESPONSIBLE FOR THE REVIEW AND APPROVAL OF TOP LEVEL EXECUTIVE MANAGEMENT COMPENSATION ANNUALLY. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS ARE EVALUATED IN ORDER TO ATTRACT THE MOST TALENTED PERSONNEL. INFORMATION IS GATHERED, ANALYZED AND DISCUSSED WITH THE INTENT ON ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G CONSULTING FEES: PROGRAM SERVICE EXPENSES 15,374,195. MANAGEMENT AND GENERAL EXPENSES 1,462. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 15,375,657. PAYROLL FEES: PROGRAM SERVICE EXPENSES 4,684. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,684.